Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2019 - 2026)

Mirum Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $270.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 4147.19% year-over-year to $270.1 million; the TTM figure through Mar 2026 stood at $303.9 million (up 1229.64% YoY), while the FY2025 annual figure was $40.1 million, up 126.8% from the prior year.
• Cash from Financing Activities was $270.1 million for Q1 2026 at Mirum Pharmaceuticals, up from $9.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $270.1 million in Q1 2026 to a low of -$329000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $45.5 million across 5 years, with a median of $8.7 million in 2025.
• Biggest YoY gain for Cash from Financing Activities was 24846.67% in 2022; the steepest drop was 153.5% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at -$329000.0 in 2022, then soared by 640.12% to $1.8 million in 2023, then jumped by 200.51% to $5.3 million in 2024, then surged by 68.52% to $9.0 million in 2025, then surged by 2901.21% to $270.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $270.1 million (Q1 2026), $9.0 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.